| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/25/2006 | EP1618179A2 Polymer-conjugated glycosylated neublastin |
| 01/25/2006 | EP1618129A2 Beta-amyloid inhibitors and use thereof |
| 01/25/2006 | EP1618109A2 Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists |
| 01/25/2006 | EP1618108A2 Triazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]pyrimidines useful as a2a adenosine receptor antagonists |
| 01/25/2006 | EP1618103A2 Polymorphs of aripiprazole |
| 01/25/2006 | EP1618099A2 Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers |
| 01/25/2006 | EP1617862A2 Botulinum neurotoxin for treating tics and obsessive compulsive behaviors |
| 01/25/2006 | EP1617856A2 Somatostatin-dopamine chimeric analogs |
| 01/25/2006 | EP1617852A2 Muscle derived cells (mdcs) for promoting and enhancing nerve repair and regeneration |
| 01/25/2006 | EP1617844A1 Treatment of neurological conditions |
| 01/25/2006 | EP1617839A1 The use of azetidinecarboxamide derivatives in therapy |
| 01/25/2006 | EP1617838A1 Composition for oral administration containing alkylene dioxybenzene derivative |
| 01/25/2006 | EP1617831A1 Combination of desoxypeganine and mecamylamine for the treatment of alcohol abuse |
| 01/25/2006 | EP1617823A1 A composition material for transmucosal delivery |
| 01/25/2006 | EP1506179B1 Benzoxazine derivatives as 5-ht6 modulators and uses thereof |
| 01/25/2006 | EP1490363B1 Methods of preparation of the 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone |
| 01/25/2006 | EP1392241A4 System for osmotic delivery of pharmaceutically active agents |
| 01/25/2006 | EP1372627B1 Use of breakers of advanced glycation endproducts for treating deleterious effects of aging and debilitating diseases |
| 01/25/2006 | EP1235825B1 Novel benzoimidazole derivatives useful as antiproliferative agents |
| 01/25/2006 | EP1158950B1 Anticonvulsant derivatives useful in treating essential tremor |
| 01/25/2006 | EP1082961B1 Sleep inducing agent comprising prostaglandin derivatives |
| 01/25/2006 | EP1080202B1 Convection-enhanced delivery of aav vectors encoding aadc |
| 01/25/2006 | EP0980427B1 Use of ulip proteins in the diagnosis and therapy of cancer and paraneoplastic neurological syndromes |
| 01/25/2006 | EP0914158B2 Pharmaceutical combination containing a compound having angiotensin ii antagonistic activity and a compound which increases the insulin-sensitivity |
| 01/25/2006 | CN1726217A Substituted pyrrolo-pyrazole derivatives as kinase inhibitors |
| 01/25/2006 | CN1726213A Imidazoquinoline derivatives as adenosine A3 receptor ligands |
| 01/25/2006 | CN1726210A Novel compounds having selective inhibiting effect at GSK3 |
| 01/25/2006 | CN1726207A Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists |
| 01/25/2006 | CN1726202A Crystalline escitalopram hydrobromide and methods for preparing the same |
| 01/25/2006 | CN1726201A Substituted piperazines,(1,4) diaszepines, and 2,5-diazabicyclo (2.2.1)iieptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists |
| 01/25/2006 | CN1726194A Novel compounds |
| 01/25/2006 | CN1726042A Benzo[d]azepine derivatives for the treatment of neurological disorders |
| 01/25/2006 | CN1726040A Use of dihydroimidazolones for the treatment of epilepsy in dogs |
| 01/25/2006 | CN1726039A Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
| 01/25/2006 | CN1726037A Treatment of headache with antipsychotics delivered by inhalation |
| 01/25/2006 | CN1726033A Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds |
| 01/25/2006 | CN1726023A Pregabalin and derivatives thereof for the treatment of fibromyalgia and other related disorders |
| 01/25/2006 | CN1726022A Pregabalin derivatives for the treatment of fibromyalgia and other disorders and its derivitive |
| 01/25/2006 | CN1726021A Alpha2delta ligands for the treatment of sexual dysfunction |
| 01/25/2006 | CN1726016A Prevention and treatment of alzheimer's disease |
| 01/25/2006 | CN1726015A Alpha2delta ligands for different pharmaceutical uses |
| 01/25/2006 | CN1724523A Long chain aromatic piperazine modified 2-(arylthio) benzylamin derivative and its preparation method and applicaltion |
| 01/25/2006 | CN1724066A Controlled release composition and method of producing the same |
| 01/25/2006 | CN1724060A Medicinal composite for treating depression, and its prepn. method |
| 01/25/2006 | CN1724023A Method for preparing Qingkailing |
| 01/25/2006 | CN1724002A Medicinal composition, and its pharmaceutical use |
| 01/25/2006 | CN1723997A Traditional Chinese medicine prepn. for treating mental disease |
| 01/25/2006 | CN1723990A Compound Chinese patent drug |
| 01/25/2006 | CN1723970A Oral liquor contg. ginseng and pearl, and its prepn. method |
| 01/25/2006 | CN1723936A Traditional Chinese medicine for treating depressive disorders, and its prepn. method |
| 01/25/2006 | CN1723909A Soft capsule contg. arasaponin (Panax Pseudoginseng leaves glucoside), and its prepn. method |
| 01/25/2006 | CN1723895A Injectable long-acting microsphere suspension contg. |
| 01/25/2006 | CN1723893A 'Huilaxitan' injection, and its prepn. method |
| 01/25/2006 | CN1723892A Sulpride dispersion tablets prepn. method |
| 01/25/2006 | CN1723878A Use of polyphenol and its oxides |
| 01/25/2006 | CN1238522C Interleukin-2 and test method of its gene in drug-stopping application |
| 01/25/2006 | CN1238507C 6 gene of neurenergen sourced from human, and application of maturation peptide fragment expressed by the gene |
| 01/25/2006 | CN1238050C Traditional Chinese medicinal paste for treating arthralgia-syndrome and preparation method thereof |
| 01/25/2006 | CN1238046C Traditional Chinese medicine for treating encephalatrophy and cerebral hemiplegia |
| 01/25/2006 | CN1238036C Pure natural instant granule for relieving alcoholism and protecting liver and preparation method thereof |
| 01/25/2006 | CN1238033C Medicine composition for treating neurasthenia |
| 01/25/2006 | CN1238019C Oil for comforting channels and collaterals |
| 01/25/2006 | CN1238000C Freeze-dried powder injection Qingkailing preparation process |
| 01/25/2006 | CN1237991C Medicine for treating amnesia and dementia |
| 01/25/2006 | CN1237962C Pharmaceutical use of asafoetide extract |
| 01/25/2006 | CN1237960C Preparation method of aspirin microsphere |
| 01/25/2006 | CN1237912C Beverage for regulating spirit |
| 01/24/2006 | US6989402 Thyroid receptor ligands and method II |
| 01/24/2006 | US6989398 Benzanilides as potassium channel openers |
| 01/24/2006 | US6989393 Ccr5 modulators benzimidazoles or benzotriazoles |
| 01/24/2006 | US6989388 Antitumor agents; anticancer agents; antiischemic agents; antiinflamamtory agents |
| 01/24/2006 | US6989385 Pyrazole compounds useful as protein kinase inhibitors |
| 01/24/2006 | US6989382 Enzyme inhibitors; pyridin-2-yl-amino-ethyl-amino-phenyl derivatives; diabetes, Alzheimer's disease, Parkinson's disease, Huntington's disease, obesity, cardiovascular disease, hypertension, polycystic ovary syndrome, ischemia, brain injury |
| 01/24/2006 | US6989376 Nervous system disorders; administering exogenous uridine compound |
| 01/24/2006 | US6989372 medicaments intended to increase the intracellular and/or extracellular level of glutathione (GSH); for example, N-(N-Acetyl-L-cysteinyl)-S-acetylcysteamine; hiv treatment |
| 01/24/2006 | US6989362 Methods of treating dopamine dysregulation using agents that regulate phosphorylation/dephosphorylation in dopamine signaling |
| 01/24/2006 | US6989271 inducing differentiation via culturing stroma cells with serum, reducing agent (beta-mercaptoethanol), retinoic acid, and forskolin; for treatment of nervous system disorders |
| 01/24/2006 | US6989270 Using polyamide nucleic acid oligomers to engender a biological response |
| 01/24/2006 | US6989260 Gene expression inhibition; for treatment of inflammatory, neurological, cardiovascular, and neoplastic tisssue growth disorders |
| 01/24/2006 | US6989159 Pharmaceutical compositions containing lithium carbonate |
| 01/24/2006 | US6989146 Stress proteins and peptides and methods of use thereof |
| 01/24/2006 | CA2368431C Melanocortin receptor ligands |
| 01/24/2006 | CA2352392C Eletriptan hydrobromide monohydrate |
| 01/24/2006 | CA2339353C Fast dissolving orally consumable films |
| 01/24/2006 | CA2261923C Pyridazino [4,5-b]-quinoline 5-oxide derivatives, their preparation and their use as glycine antagonists |
| 01/24/2006 | CA2255824C Nitrate esters and their use for neurological conditions |
| 01/24/2006 | CA2205757C Pyridazinone derivatives and their use as inhibitors of prostaglandin g/h synthase i and ii(cox i and ii) |
| 01/24/2006 | CA2195747C New 3-substituted 3h-2,3-benzodiazepine derivatives, their preparation and use as medicaments |
| 01/19/2006 | WO2006006751A1 A composition comprising purified extract of wild ginseng having neuronal cell protecting activity |
| 01/19/2006 | WO2006006741A1 Fused benzamide compound and vanilloid receptor 1 (vr1) activity inhibitor |
| 01/19/2006 | WO2006006740A1 3-aminobenamide compound and vanilloid receptor 1 (vr1) activity inhibitor |
| 01/19/2006 | WO2006005802A1 Method for stimulating mammalian cells and mammalian cell |
| 01/19/2006 | WO2006005707A2 Method for preventing and treating alzheimer´s disease |
| 01/19/2006 | WO2006005667A2 Polypeptide protracting tags comprising a tetrazole moiety |
| 01/19/2006 | WO2006005591A1 Polypeptide species useful for the treatment of neurological disorders |
| 01/19/2006 | WO2006005588A1 Polypeptide species useful for the treatment of neurological disorders |
| 01/19/2006 | WO2006005586A2 New polypeptide species specific to cerebrospinal fluid |
| 01/19/2006 | WO2004028472A3 THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING INTERFERON-β |
| 01/19/2006 | US20060015054 External plaster containing 4-biphenylacetic acid |
| 01/19/2006 | US20060014982 Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide |